Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KTTA 
Pasithea Therapeutics Corp (KTTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: KTTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.86% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.44M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.27 | 52 Weeks Range 0.65 - 4.48 | Updated Date 10/17/2025 |
52 Weeks Range 0.65 - 4.48 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -49.52% | Return on Equity (TTM) -85.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6103748 | Price to Sales(TTM) 42.15 |
Enterprise Value -6103748 | Price to Sales(TTM) 42.15 | ||
Enterprise Value to Revenue 277.44 | Enterprise Value to EBITDA 2.9 | Shares Outstanding 7443577 | Shares Floating 7331253 |
Shares Outstanding 7443577 | Shares Floating 7331253 | ||
Percent Insiders 1.51 | Percent Institutions 11.17 |
Upturn AI SWOT
Pasithea Therapeutics Corp
Company Overview
History and Background
Pasithea Therapeutics Corp. is a biotechnology company focused on the research and development of new and effective treatments for central nervous system (CNS) disorders. It was founded in 2019 and has since been focused on the development of novel therapeutics, especially those with a focus on psilocybin-based treatments. They also work on immunomodulatory therapies.
Core Business Areas
- CNS Therapeutics: Focuses on developing treatments for neuropsychiatric disorders such as depression, anxiety, and PTSD, leveraging psilocybin and other novel compounds.
- Immunomodulatory Therapies: Involves the development of therapies aimed at modulating the immune system to treat various autoimmune and inflammatory conditions.
Leadership and Structure
The company has a management team with experience in drug development and clinical research. The organizational structure is typical of a biotech company, with departments focused on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Psilocybin-Based Therapies: Pasithea is developing psilocybin-based therapies for various mental health disorders. Currently in clinical trials. Market share is not yet applicable as no products are commercially available. Competitors in this space include Compass Pathways (CMPS) and ATAI Life Sciences (ATAI).
- PAS004 (Neurokinin-3 receptor antagonist): Being tested for women's health conditions. Market share is currently not applicable as the product is in clinical trials. Competitors in this space include Neurocrine Biosciences (NBIX).
Market Dynamics
Industry Overview
The biotechnology industry, particularly in the CNS and mental health space, is experiencing significant growth due to increasing prevalence of mental health disorders and a growing acceptance of psychedelic-assisted therapies. The market is competitive and heavily regulated.
Positioning
Pasithea is positioned as an innovator in the psychedelic medicine and CNS therapeutic space, focusing on novel treatments and strategic partnerships. They are smaller than some of their key competitors.
Total Addressable Market (TAM)
The global CNS therapeutics market is projected to reach hundreds of billions of USD. Pasithea's TAM is significant, particularly in specific niche areas like treatment-resistant depression and PTSD using psychedelic therapies, but their positioning is dependent on the success of clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Focus on innovative therapies (psilocybin, immunomodulation)
- Experienced management team
- Strategic partnerships
- Early mover advantage in specific therapeutic areas
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Small market capitalization
- Regulatory uncertainty surrounding psychedelic therapies
Opportunities
- Growing market for mental health treatments
- Potential for breakthrough therapies
- Increasing acceptance of psychedelic medicine
- Partnerships with larger pharmaceutical companies
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Clinical trial failures
- Negative public perception of psychedelics
Competitors and Market Share
Key Competitors
- CMPS
- ATAI
- NBIX
Competitive Landscape
Pasithea faces competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its focus on innovative therapies and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the company's progression through preclinical and clinical stages of drug development.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals for its key therapeutic candidates. Analyst estimates vary widely due to the inherent uncertainty in biotech investments.
Recent Initiatives: Recent initiatives include advancing clinical trials for psilocybin-based therapies and forming strategic partnerships to expand its pipeline and capabilities.
Summary
Pasithea Therapeutics Corp. is a high-risk, high-reward biotechnology company focused on innovative CNS and immunomodulatory therapies. Its success depends on clinical trial outcomes and regulatory approvals. The company is in a very early stage and its growth prospects are uncertain. The company needs to secure funding and demonstrate clinical efficacy to succeed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com | ||
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.